Moleculin Biotech ( (MBRX) ) has released its Q4 earnings. Here is a breakdown of the information Moleculin Biotech presented to its investors.
Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing treatments for hard-to-treat cancers and viruses, with its lead program, Annamycin, targeting relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases.
In its latest earnings report, Moleculin Biotech highlighted significant progress in its clinical trials, particularly the Phase 3 MIRACLE trial for AML, and announced several regulatory and clinical milestones achieved in 2024.
Key financial metrics showed a decrease in research and development expenses to $17.7 million and general and administrative expenses to $8.8 million for 2024. The company reported a net loss of $21.8 million, with cash and cash equivalents of $4.3 million as of the end of the year. Moleculin also secured $9.3 million in financing in early 2025 to support its operations.
Strategically, Moleculin expanded its global exclusivity for Annamycin and received positive FDA guidance, which could accelerate its MIRACLE trial timeline. The company also completed enrollment in a Phase 2 trial for soft tissue sarcoma lung metastases, with data expected soon.
Looking ahead, Moleculin remains focused on advancing Annamycin’s development and achieving key milestones in 2025, including initial data readouts from its pivotal trials, which could significantly impact its regulatory pathway and future growth prospects.